Klotho Neurosciences, Inc. is a biopharmaceutical company. The Company is engaged in the development of disease-modifying cell and gene therapies using a patented secreted form of the anti-aging Klotho gene (s-KL) to transform the treatment of neurodegenerative and age-related disorders, such as amyotrophic lateral sclerosis (ALS), Alzheimer's, and Parkinson's disease. The Company’s portfolio consists of its proprietary cell and gene therapy programs using deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) as therapeutics and diagnostics. Its gene therapy programs include KLTO-202, KLTO-101, and KLTO-301. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The Company has licensed the anti-aging protein called α-Klotho for gene therapy to stop the progression of, or prevent, neurodegenerative diseases.